A Phase II Study of AG-120 for Patients with IDH1-Mutant Chondrosarcoma

Share
Print

Full Title

Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma (MCT)

Purpose

The purpose of this study is to assess the safety and effectiveness of the drug AG-120 (ivosidenib) in patients with recurrent or metastatic chondrosarcoma (a cancer of the bone or soft tissue) whose tumors contain a mutated form of the IDH1 gene. AG-120 blocks an abnormal form of the IDH1 protein. Abnormal IDH1 causes too much of a substance called 2-HG to be produced, which can fuel cancer growth. AG-120 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic chondrosarcoma that contains mutated IDH1.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ciara Kelly at 646-888-4312.

Protocol

19-393

Phase

II

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Co-Investigators